Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC lowered its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 314,046 shares of the medical equipment provider's stock after selling 24,878 shares during the quarter. Natixis Advisors LLC owned 0.14% of Hologic worth $22,639,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. General Partner Inc. purchased a new position in Hologic during the fourth quarter valued at $26,000. Venturi Wealth Management LLC lifted its stake in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. lifted its stake in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HOLX. Royal Bank of Canada decreased their target price on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 6th. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Evercore ISI reduced their target price on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research report on Thursday, February 6th. Wolfe Research began coverage on shares of Hologic in a research report on Friday, December 13th. They set a "peer perform" rating on the stock. Finally, William Blair reiterated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $84.62.

Hologic Trading Up 0.8 %

NASDAQ:HOLX traded up $0.46 during trading hours on Friday, reaching $61.47. 7,416,503 shares of the stock were exchanged, compared to its average volume of 1,746,772. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67. The business has a 50-day moving average of $66.26 and a two-hundred day moving average of $74.19. The company has a market capitalization of $13.79 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.